Alkhouri, Naim

Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH

Ratziu, V., Harrison, S. A., Loustaud-Ratti, V., Bureau, C., Lawitz, E., Abdelmalek, M., Alkhouri, N., Francque, S., Girma, H., Darteil, R., et al. (2023) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 101

Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis

Chang, D., Truong, E., Mena, E. A., Pacheco, F., Wong, M., Guindi, M., Todo, T. T., Noureddin, N., Ayoub, W., Yang, J. D., et al. (2023) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 92

Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes ( EDICT )

Lavynenko, O., Abdul‐Ghani, M., Alatrach, M., Puckett, C., Adams, J., Abdelgani, S., Alkhouri, N., Triplitt, C., Clarke, G. D., Vasquez, J. A., et al. (2022) · Diabetes, Obesity and Metabolism

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 44

Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials

Wong, V. W.-S., Tak, W. Y., Goh, G. B. B., Cheng, P.-N., Lawitz, E. J., Younossi, Z. M., Vuppalanchi, R., Younes, Z., Alkhouri, N., Wang, L., et al. (2023) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 31

Mortality outcomes in individuals with MASLD versus MASLD and increased alcohol intake

Aboona, M. B., Danpanichkul, P., Chen, V. L., Rangan, P., Kim, D., Alkhouri, N., Fallon, M. B., Noureddin, M., Arab, J. P., & Wijarnpreecha, K. (2024) · Journal of Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 29

Safety and efficacy of combination therapies including cilofexor/ firsocostat in patients with bridging fibrosis and cirrhosis due to NASH: Results of the phase 2b ATLAS trial

Loomba, R., Noureddin, M., Kowdley, K., Kohli, A., Sheikh, A., Neff, G., Bhandari, B. R., Gunn, N. T., Caldwell, S., Goodman, Z., et al. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentOrgan Transplantation Techniques and Outcomes

Cited by 9

THU-242 Comparison ofmachine learning model (MASML), VCTE, and FIB-4 scores for predicting the presence of MASLD in a large cohort of patients in the U.S. using the NHANES database

Noureddin, M., Rubinsztain, J., Taub, K., Chang, D. Y., Harrison, S. A., & Alkhouri, N. (2024) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1

THU-233 External validation of machine learning model (MASML) adjusted for prevalence for determining the histologic severity of MASLD in a large cohort of patients with biopsy-proven disease

Alkhouri, N., Rubinsztain, J., Taub, K., Harrison, S. A., Chang, D. Y., & Noureddin, M. (2024) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1